

## Disclosures

### Personal Commercial (3)

| Company Name                 | Relationship Category    | Compensation Level       | Topic Area(s) |
|------------------------------|--------------------------|--------------------------|---------------|
| Self                         |                          |                          |               |
| Abbott Laboratories          | Research/Research Grants | Significant (>= \$5,000) |               |
| Amgen Inc.                   | Research/Research Grants | Modest (< \$5,000)       |               |
| Janssen Pharmaceuticals, Inc | Research/Research Grants | Modest (< \$5,000)       |               |

### Additional Personal Commercial Disclosures for Education Activities (5)

| Company Name                | Relationship Category                        | Compensation Level       | Topic Area(s)            |
|-----------------------------|--|--------------------------|--------------------------|
| Self                        |  |                          |                          |
| Amgen Inc.                  | Research/Research Grants                     | Modest (< \$5,000)       |                          |
| Amgen Inc.                  | Research/Research Grants                     | Modest (< \$5,000)       |                          |
| AstraZeneca Pharmaceuticals | Research/Research Grants                     | Significant (>= \$5,000) |                          |
| Boston Scientific           | Research/Research Grants<br>† COMPLETE trial | Significant (>= \$5,000) |                          |
| Jannsen                     | Research/Research Grants                     | Significant (>= \$5,000) | Acute Coronary Syndromes |

### Personal Organizational or Other Non-Commercial (0)

No disclosures on record

### Clinical Trial Enroller (5)

| Trial Name  | Trial Sponsor       | Trial Funding Source |
|-------------|---------------------|----------------------|
| Triluminate | Abbott Laboratories |                      |
| Ocean(a)    | Amgen               |                      |
| Aegis 2     | CSL Behring         |                      |
| Aegis 2     | CSL Behring         |                      |
| Reverse it  | PhaseBio            |                      |

### Institutional Financial Decision-Making Role (0)

No disclosures on record

### Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

## Agreement

### Certified Education Attestation | Signed on 9/19/2022

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

### Confidentiality, Disclosure and Assignment Agreement | Signed on 9/19/2022

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

### Embargo | Signed on 9/19/2022

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

## **ACC and Disclosures**

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.